Cell Metabolism

RET-STUDY-P002

Coskun T, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist for glycemic control and weight loss. Cell Metabolism. 2022. DOI: 10.1016/j.cmet.2022.07.013. PMID: 35985340. NCT03841630. https://www.cell.com/cell-metabolism/

Study design

Record details

Design: Identity, discovery, and analytical records

Evidence record

Endpoints, findings, and limitations

Limitations

This study record is an evidence-index entry. Interpret the design, material, population or model, endpoints, findings, and limitations only within the linked approved source and compound evidence map; do not transfer outcomes across compounds, materials, cohorts, or models.

Reports and sources

Reference ledger

P002Identity, discovery, and analytical records

Cell Metabolism

Coskun T, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist for glycemic control and weight loss. Coskun T, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist for glycemic control and weight loss. Cell Metabolism. 2022. DOI: 10.1016/j.cmet.2022.07.013. PMID: 35985340. NCT03841630. https://www.cell.com/cell-metabolism/fulltext/S1550-4131(22)00312-6(2022). DOI: 10.1016/j.cmet.2022.07.013